Health care convalescence

Health care stocks are playing catch-up after about six quarters of underperformance, with many stocks still in the bargain bin, particularly beaten-up biotechs. Is health care a buy? We believe in a selective approach; a dynamic of haves versus have-nots means that health care is increasingly all about stock picking.

Highlights
- Health care stocks look cheap compared with their own history and other sectors. This reflects drug pricing pressures, waning growth opportunities with few blockbuster drugs in pipelines and uncertainty over U.S. health care reform.
- We see innovation, a lifting of U.S. health care policy uncertainty and industry consolidation as potential catalysts. U.S. tax reforms encouraging repatriation of overseas cash could trigger M&A as large-cap drug makers seek to “buy growth.”
- Health care has higher dispersion and lower stock correlation than other sectors. This reflects variation in innovation cycles, drug patents and pipelines. It reinforces the importance of picking winners and avoiding losers. We currently see the most opportunities in biotech, medical devices and the U.S. managed care industry.

Out of favor
Health care stocks have historically traded at a premium to the broader equity market, partly reflecting their growth characteristics and popularity as a source of income. Yet today some sub-industries such as biotech sell at a discount. Many trade near the bottom of their historical valuation range, as the Bargain bin chart shows.
Pricing problems
The need to care for aging populations means health care is a growth business. Costs have surged over the past two decades. In the U.S., health care spending totaled more than 16% of gross domestic product in 2015, up from single digits in the 1970s and about 12% in 1995. Germany, France, Japan and the UK tell a similar story. See the It’s a growth business chart.

Health care is growing beyond developed markets as well. China’s spending as a share of GDP has almost doubled over the past two decades—albeit from much lower levels than in the developed world—and is set to head higher as its population becomes more prosperous and older.

The challenge for drug makers is that politicians, regulators and consumers are increasingly clamoring to curb growth in drug prices. U.S. prescription drug prices rose 5.2% in 2016, the largest increase since 2001, according to the Bureau of Economic Analysis. This makes pharma and biotech easy targets, particularly given average gross margins of more than 90% in the latter, according to Bloomberg data as of March. In the U.S., a Republican attempt to “repeal and replace” Obamacare leads to more political uncertainties in the U.S. market for some health insurers and hospitals.

Pricing pressures are spreading to the emerging world as governments work to expand safety nets and cap price increases. Emerging markets were once seen as the industry’s savior, but are now morphing into a volume game. As in Europe’s developed markets, companies benefit from increased sales while the ability to raise prices vanishes. The ultimate defense against drug pricing pressure? Innovation. Innovative products command higher prices. This is why we believe it is key to assess the product pipelines of individual companies.

It’s a growth business
Health care expenditures vs. GDP, 1995 and 2015

Doing deals

Taking the pulse
Many big drug makers are struggling to maintain past rates of growth. There is not enough in the product pipeline to replace yesterday’s blockbuster drugs, many of which will come off patent in the coming years and face competition from generics. This is reflected in sluggish earnings estimates for the health care sector overall. Consensus forecasts point to earnings-per-share (EPS) growth of just 5% globally in 2017, according to Thomson Reuters data. Only telecoms and utilities have poorer growth prospects.

We also see M&A activity acting as a catalyst for industry consolidation. With most large-cap pharma companies in the “mature” stage of product development, many are seeking to buy growth. We think M&A will pick up in the health care sector after dipping in 2016. Pharmaceutical companies may dominate the activity in 2017 if history is a guide. They were responsible for more than half of deals in the 2014 and 2015 boom years. See the Doing deals chart.

Health care is about more than just drug makers. We see opportunities in medical device makers, for example. The innovators here offer similar characteristics to consumer staples companies, yet more growth and cheaper valuations, we believe. We also like selected companies in the U.S. managed care sector, a type of low-cost health insurer that stands to benefit from deregulation and efforts to curb overall health care costs. Lastly, we see indiscriminate selling in the biotech sector dragging down some companies with strong pipelines and higher growth potential. Despite politicians’ tweets decrying the high price of many popular drugs, we do not expect any systemic changes to U.S. drug pricing policy. Another potential positive is a proposal by President Donald Trump that could help streamline drug approvals.
Dissecting deals

Large drug companies generate huge amounts of free cash flow. U.S. companies have parked much of this cash overseas to avoid high U.S. corporate taxes on repatriated earnings. Meanwhile, they have been taking advantage of still-low rates to pay for dividends, share buybacks, capital expenditures and, during the 2014-2015 boom, deals. The surge in M&A during that period was accompanied by a spike in corporate leverage as well as a decrease in cash. See the Cash-rich borrowers chart. Rising interest rates could make debt-financed deals less attractive.

U.S. tax reforms look likely to include a one-off tax on overseas cash. This could prompt companies to bring much of their cash home, providing a catalyst for another wave of industry consolidation. Few targets are big enough to make a difference to a mega cap’s revenue growth. The small- and mid-cap players with products that could hold sway over entire markets, so-called “category killers,” are set to benefit. Some are already looking pricey, however. Price-earnings ratios of biotechs in the mid-cap S&P 400 have jumped by 64% since November, Thomson Reuters data show.

What happens if few deals get done? Companies might return more cash to shareholders in the form of dividends or share buybacks. We do see opportunities in pharma for income investors seeking dividend growth. Yet selectivity is key; average payout ratios in the sector stand at 46%, the highest in more than two decades, according to Bloomberg data as of March. The bottom line is companies need to find ways to generate growth. We advocate considering undervalued companies with promising drug pipelines – and waiting for a crystallizing event such as a regulatory approval, successful commercial adoption or takeover.

Cash-rich borrowers

U.S. pharma companies cash vs. leverage, 1992-2016

Sources: BlackRock Investment Institute and Bloomberg, March 2017. Notes: The green line shows total cash balances for members of the S&P 500 pharmaceutical index while the blue line shows net debt as a percentage of earnings before interest, tax, depreciation and amortization (EBITDA).

Stock pickers welcome

Average intra-sector stock correlations, 2000-2017

Sources: BlackRock Investment Institute, S&P Global and Thomson Reuters, March 2017. Notes: The bars show the average 60-day intra-sector stock correlation for selected S&P 500 sectors. A low reading implies greater variation in stock performance within a sector. A high reading means companies within a sector move almost in lockstep. Biopharma includes biotech, pharma and life sciences tools and services. Medical devices and services includes health care equipment and supplies, health care providers and services and health care technology.

To have and have not

Health care means different things to different investors. It has been seen as a refuge (especially after the financial crisis), a source of income, a high growth area and sometimes a volatile sector subject to the whims of politicians’ tweets. But we believe an appropriate strategy is focusing on the merits of individual stocks rather than the attributes of the entire sector. The health-care sector is made up of the haves (those with potential category-killer medical products including drugs, devices and diagnostics) and the have-nots (companies in areas that face generic competition or product obsolescence).

The low correlation of companies’ stock performance within the biopharma and medical devices and services subsectors since 2000 supports this idea. See the Stock pickers’ welcome chart. This makes health care a happy hunting ground for stock pickers. The picture is different for energy, telecoms and financials, where companies within the same sector have historically tended to move more in lockstep.

Our bottom line: We see demand for health care products and services rising in both developed and emerging markets. Worries about drug pricing and other policy risks are largely reflected in valuations, in our view. We see opportunities in biotech, medical device makers, U.S. managed care companies and selected big pharma with promising drug pipelines. Investors can wait for a catalyst such as a takeover (selected small and mid caps) or pocket steady dividends until the market reprises the value of the pipeline. Our key view: Be selective when investing in health care.
This material is prepared by BlackRock and is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of March 2017 and may change as subsequent conditions vary. The information and opinions contained in this material are derived from proprietary and nonproprietary sources deemed by BlackRock to be reliable, are not necessarily all inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by BlackRock, its officers, employees or agents. This material may contain 'forward-looking' information that is not purely historical in nature. Such information may include, among other things, projections and forecasts. There is no guarantee that any forecasts made will come to pass. Relevance upon information in this material is at the sole discretion of the reader. This material is intended for information purposes only and does not constitute investment advice or an offer or solicitation to purchase or sell in any securities, BlackRock funds or any investment strategy nor shall any securities be offered or sold to any person in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. In the U.S., this material is intended for public distribution. In the EU by BlackRock Investment Management (UK) Limited (authorised and regulated by the Financial Conduct Authority). Registered office: 12 Throgmorton Avenue, London, EC2N 2DL. Registered in England No. 2020394. Tel: 020 7743 3000. For your protection, telephone calls are usually recorded. BlackRock is a trading name of BlackRock Investment Management (UK) Limited. This material is for distribution to Professional Clients (as defined by the FCA Rules) and Qualified Investors and should not be relied upon by any other persons. For qualified investors in Switzerland, this material shall be exclusively made available to, and directed at, qualified investors as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended. This information can be distributed in and from the Dubai International Financial Centre (DIFC) by BlackRock Advisors (UK) Limited - Dubai Branch which is regulated by the Dubai Financial Services Authority (‘DFSA’) and is only distributed at ‘Professional Clients’ and no other person should rely upon the information contained within it. Neither the DFSA or any other authority or regulator located in the GCC or MENA region has approved this information. Issued in the Netherlands by the Amsterdam branch office of BlackRock Investment Management (UK) Limited: Amstelplein 1, 1096 HA Amsterdam. Tel: 020 - 549 5200. For more information please see the website: www.blackrock.nl. Issued in Australia and New Zealand by BlackRock Investment Management (Australia) Limited ABN 13 006 165 975 AFSL 230 523 (BIMAL) for the exclusive use of the recipient who warrants by receipt of this material that they are a wholesale client and not a retail client as those terms are defined under the Australian Corporations Act 2001 (Cth) and the New Zealand Financial Advisers Act 2008 respectively. This material contains general information only and does not constitute financial product advice. This material has been prepared without taking into account any person’s objectives, financial situation or needs. Before making any investment decision based on this material, a person should assess whether the information is appropriate having regard to the person’s objectives, financial situation and needs and consult their financial, tax, legal, accounting or other professional advisor about the information contained in this material. This material is not intended for distribution to, or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. BIMAL is the issuer of financial products and acts as an investment manager in Australia. BIMAL does not offer financial products to persons in New Zealand who are retail investors (as that term is defined in the Financial Markets Conduct Act 2013 (FMCA)). This material does not constitute or relate to such an offer. To the extent that this material does constitute or relate to such an offer of financial products, the offer is only made to, and capable of acceptance by, persons in New Zealand who are wholesale investors (as that term is defined in the FMCA). BIMAL is a part of the global BlackRock Group which comprises of financial product issuers and investment managers around the world. This material has not been prepared specifically for Australian or New Zealand investors. It may contain references to dollar amounts which are not Australian or New Zealand dollars and may contain financial information which is not prepared in accordance with Australian or New Zealand law or practices. BIMAL, its officers, employees and agents believe that the information in this material and the sources on which the information is based (which may be sourced from third parties) are correct as at the date specified in this material. While every care has been taken in the preparation of this material, no warranty of accuracy or reliability is given and no responsibility for this information is accepted by BIMAL, its officers, employees or agents. Except where contrary to law, BIMAL excludes all liability for this information. Past performance is not a reliable indicator of future performance. Investing involves risk including loss of principal. No guarantee as to the capital value of investments nor future returns is made by BIMAL or any company in the BlackRock Group. In Singapore, this is issued by BlackRock (Singapore) Limited (Co. registration no. 200010143N) for use only with institutional investors as defined in Section 4A of the Securities and Futures Act, Chapter 289 of Singapore. In Hong Kong, this material is issued by BlackRock Asset Management North Asia Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong. This material is for distribution to ‘Professional Investors’ (as defined in the Securities and Futures Ordinance (Cap.571 of the laws of Hong Kong) and any rules made under that ordinance) and should not be relied upon by any other persons or redistributed to retail clients in Hong Kong. In Korea, this material is for Professional Investors only. In Japan, this is issued by BlackRock Japan Co., Ltd. (Financial Instruments Business Operator: The Kanto Regional Financial Bureau. License No.375, Association Memberships: Japan Investment Advisers Association, The Investment Trusts Association, Japan, Japan Securities Dealers Association, Type II Financial Instruments Firms Association.) for Professional Investors only (Professional Investor is defined in Financial Instruments and Exchange Act) and for information or educational purposes only, and does not constitute investment advice or an offer or solicitation to purchase or sells in any securities or any investment strategies. In Taiwan, independently operated by BlackRock Investment Management (Taiwan) Limited. Address: 2F, No. 95, Tun Hwa South Road, Section 2, Taipei 106, Taiwan. Tel: (02)23261600. In Canada, this material is intended for permitted clients only. In Latin America and Iberia, this material is for educational purposes only and does not constitute investment advice nor an offer or solicitation to sell or a solicitation of an offer to buy any shares of any fund (nor shall any such shares be offered or sold to any person) in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities law of that jurisdiction. If any funds are mentioned or referred to in this material, it is possible that some or all of the funds have not been registered with the securities regulator of Brazil, Chile, Colombia, Mexico, Panama, Peru, Portugal, Spain, Uruguay or any other securities regulator in any Latin American country and thus might not be publicly offered within any such country. The securities regulators of such countries have not confirmed the accuracy of any information contained herein. The information provided here is neither tax nor legal advice. Investors should speak to their tax professional for specific information regarding their tax situation. Investment involves risk including possible loss of principal. International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation, and the possibility of substantial volatility due to adverse political, economic or other developments. These risks are often heightened for investments in emerging/developing markets or smaller capital markets.